1. Antibody-drug Conjugate/ADC Related
    Cell Cycle/DNA Damage
    Cytoskeleton
  2. ADC Cytotoxin
    Microtubule/Tubulin

Paclitaxel 

Cat. No.: HY-B0015 Purity: 99.46%
Handling Instructions

Paclitaxel is a potent anticancer agent known to promote microtubule (MT) assembly, inhibit MT depolymerization, and change MT dynamics required for mitosis and cell proliferation.

For research use only. We do not sell to patients.
Paclitaxel Chemical Structure

Paclitaxel Chemical Structure

CAS No. : 33069-62-4

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
50 mg $50 In-stock
100 mg $80 In-stock
500 mg $140 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Paclitaxel is a potent anticancer agent known to promote microtubule (MT) assembly, inhibit MT depolymerization, and change MT dynamics required for mitosis and cell proliferation.

IC50 & Target

IC50: 4 nM (MT)

In Vitro

Paclitaxel at 0.1, 0.5, and 1 μM reduces the proliferation and survival of CCRF-HSB-2 cells in a dose-dependent fashion and that the IC50 value of taxol is about 0.25 μM[1]. Paclitaxel directly associates with the endoplasmic reticulum to stimulate the release of calcium into the cytosol, contributing to the induction of apoptosis[2].

In Vivo

In a SCID mouse xenograft model, low dose metronomic Paclitaxel treatment decreases lung dissemination of EGI-1 cells without significantly affecting their local tumor growth[3]. Low doses of paclitaxel promot liver metastasis in mouse xenografts, which correlats with changes in estrogen metabolism in the host liver[4].

Clinical Trial
Sponsor Condition Start Date Phase
Roche Holding AG Breast tumor 2010-10-31 Phase 4
Aarhus University Hospital Angina 2004-08-31 Phase 4
Roche Holding AG Metastatic breast cancer 2010-03-31 Phase 4
Eurocor GmbH Restenosis 2010-02-28 Phase 4
Taipei-Veterans General Hospital Metastatic lung cancer 2008-04-30 Phase 4
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.1711 mL 5.8554 mL 11.7108 mL
5 mM 0.2342 mL 1.1711 mL 2.3422 mL
10 mM 0.1171 mL 0.5855 mL 1.1711 mL
Kinase Assay
[1]

To determine which caspases are involved in apoptosis induced by taxol, caspase-3 inhibitor (DEVD-CHO), caspase-6 inhibitor (Z-VEID-FMK), caspase-8 inhibitor (Z-IETD-FMK or IETD-CHO), caspase-9 inhibitors (Z-LEHD-FMK or LEHD-CHO), and caspase-10 inhibitor (Z-AEVD-FMK) are used. These caspase inhibitors are dissolved in dimethyl sulfoxide (Me2SO); the final concentration of Me2SO is 0.1%. Cells (5×105) are preincubated in the presence or absence of 100 μM each of these inhibitors for 3 h at 37°C then treated with or without 0.1, 0.5, and 1 μM Paclitaxel for 48 h and processed for annexin V binding assay.

Cell Assay
[1]

1×104 cells are plated in 100 μL of the growth medium in the presence or absence of increasing concentrations (0.1-1 μM) of taxol in 96-well plates and cultured at 37°C in 5% CO2 for 12-48 h. The cells are then incubated with 25 μL of MTT (5 mg/mL) at 37°C for 4 h. After dissolving the crystals with 0.04 N HCl in isopropanol, the plates are read in a microplate reader at 570 nm. The concentration of drug that inhibits cell survival by 50% (IC50) is determined from cell survival plots.

References
M.Wt

853.91

Formula

C₄₇H₅₁NO₁₄

CAS No.

33069-62-4

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 36 mg/mL

Purity: 99.46%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Paclitaxel
Cat. No.:
HY-B0015
Quantity: